Corvus Pharmaceuticals, Inc. (CRVS) vs Janux Therapeutics, Inc. (JANX)

Corvus Pharmaceuticals, Inc. and Janux Therapeutics, Inc. are both Biotechnology companies. Corvus Pharmaceuticals, Inc. and Janux Therapeutics, Inc. are of similar size ($1.0B and $992.6M). Corvus Pharmaceuticals, Inc. has the higher net margin (0.00% vs −427.5%) and the lower return on invested capital (−352.5% vs 0.00%). Across the 13 metrics below, Janux Therapeutics, Inc. leads on 7 and Corvus Pharmaceuticals, Inc. on 6.

Valuation

Metric CRVS JANX Biotechnology median
P/E n/m n/m 7.88
P/S n/m 42.74 11.47
P/B 4.76 1.11 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 2.29 10.73
Earnings yield (5.25%) (10.06%) (28.84%)
Free cash flow yield (4.21%) (4.09%) (23.03%)

Profitability

Metric CRVS JANX Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (598.15%) 0.00%
Net margin 0.00% (427.47%) 0.00%
Free cash flow margin 0.00% (174.69%) 0.00%
Return on equity (18.98%) (10.70%) (57.72%)
Return on assets (17.64%) (10.06%) (49.22%)
Return on invested capital (352.49%) 0.00% 0.00%

Growth

Metric CRVS JANX Biotechnology median
Revenue growth (TTM) — 83.92% 5.64%
EPS growth (last fiscal year) 81.21% (42.97%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRVS JANX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.16 16.35 4.73
Net debt to EBITDA 1.28 5.58 0.96

Dividend

Metric CRVS JANX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CRVS JANX Biotechnology median
Market cap 992.63m 1.02b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack